Moreover, the ongoing controversy on the relationship between sodium glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputations emphasized that there may be a complex interaction between PAOD, kidney disease, and diabetes [37,38]. Here, SLC5A2 is linked to kidney disorder.